
WHAT IS CLAIMED IS:

1. Use of a pegylated type I interferon in the manufacture of a medicament for the treatment of a myeloproliferative disease in a subject, wherein the pegylated type I interferon is provided as a dose of from 50 to 540 µg that is to be administered to a subject once every 3 to 8 weeks for a treatment period, wherein the myeloproliferative disease is myelofibrosis, polycythemia vera, or essential thromobocythemia, and the pegylated type I interferon is



, in which mPEG has a molecular weight of 20 kD and IFN is an interferon-α_{2b}.

2. The use of claim 1, wherein the pegylated type I interferon is administered once every is 4 to 8 weeks, such as 4 weeks.

3. The use of Claim 1 or Claim 2, wherein the treatment period is at least 2 to 12 months, such as 12 months.

4. The use of any of claims 1-3, wherein:

(a) a constant dose of the pegylated type I interferon is to be administered; and/or


(b) the pegylated type I interferon is to be administered to a subject who had previously been administered a type I interferon once per week for at least 2 to 12 months.

5. Use of a pegylated type I interferon in the manufacture of a medicament for the treatment of a myeloproliferative disease in a subject, wherein:

the pegylated type I interferon is provided as a dose of from 50 to 540 µg that is to be administered to a subject at a first regular interval for a first treatment period, the first interval being once every 1 to 4 weeks; and

the pegylated type I interferon is provided as a dose of from 50 to 540 µg that is to be administered to a subject at a second regular interval for a second treatment period, the

second interval being once every 3 to 8 weeks, wherein the myeloproliferative disease is myelofibrosis, polycythemia vera, or essential thromobocythemia, and the pegylated type I interferon is



, in which mPEG has a molecular weight of 20 kD and IFN is an interferon-α_{2b}.

6. The use of claim 5, wherein the total amount of the pegylated type I interferon to be administered to the subject per a given period during the second treatment period is lower than the total amount to be administered per the given period during the first treatment period.

7. The use of claim 6, wherein the first treatment period continues until the subject exhibits (i) normalization of at least one hematological parameter and/or (ii) at least 50% reduction of JAK2V617F allelic burden.

8. The use of claim 7, wherein the at least one hematological parameter is hematocrit, white blood cell count (WBC), or platelet count.

9. The use of claim 8, wherein the hematocrit is less than 45%, the WBC is less than or equal to 10 x 10^9/L, and the platelet count is less than or equal to 400 x 10^9/L.

10. The use of claim 9, wherein the first interval is once every 1 to 2 weeks.

11. The use of claim 10, wherein the second interval is once every 4 weeks.

12. The use of any of claims 5-11, wherein:

(a) the second treatment period is at least 2 to 12 months; and/or

(b) the first treatment period is at least 2 to 12 months.

13. The use of Claim 4, wherein the pegylated type I interferon is to be administered to a subject who had previously been administered a 12.5 to 25 μg dose of a type I interferon once per week for at least 2 to 12 months.